Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGER | Q15109 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.47 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.45 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.45 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.45 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.45 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.45 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.45 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29028661 | 0.86 | MCHR1 (0.59) | AGERMAPTMCOLN3CYP2C9CYP2C19 | |
| SCHEMBL3555916 | 0.83 | TDP1 (0.58) | CYP2C8CYP2C9CYP2C18CYP2C19MEN1 | |
| Ditolamide SCHEMBL2110790 | 0.81 | CA9 (0.64) | GLAMEN1KMT2ACNR2SMN1; SMN2 | |
| SCHEMBL10282765 | 0.79 | MAPT (0.53) | AGERMAPTMCOLN3GLAMCHR1 | |
| SCHEMBL28830600 | 0.79 | AGER (0.44) | AGERMAPTMCOLN3CYP2C9CYP2C19 | |
| SCHEMBL11779484 | 0.78 | PSEN1 (0.48) | AGERMAPTMCOLN3CYP2C8CYP2C9 | |
| SCHEMBL29144994 | 0.76 | MAPT (0.46) | AGERMAPTMCOLN3CYP2C8CYP2C9 | |
| SCHEMBL11704263 | 0.76 | MAPT (0.46) | AGERMAPTMCOLN3CYP2C8CYP2C9 | |
| SCHEMBL7930094 | 0.76 | AGER (0.47) | AGERMAPTMCOLN3CYP2C9CYP2C19 | |
| SCHEMBL9361266 | 0.76 | CA9 (0.63) | GLAMEN1KMT2ACNR2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9861652-B2 | 2′ Fluoronucleosides | EMORY UNIVERSITY (US) | 2018-01-09 | — | — | US | disclosed |
| US-20160158266-A1 | 2' FLUORONUCLEOSIDES | EMORY UNIVERSITY | 2016-06-09 | — | — | US | disclosed |
| US-9180138-B2 | 2′-fluoronucleosides | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20130157971-A1 | 2'-FLUORONUCLEOSIDES | SCHINAZI RAYMOND F (US) | 2013-06-20 | — | — | US | disclosed |
| US-8168583-B2 | 2-fluoronucleosides | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| EP-2392580-A1 | 2'-fluoronucleosides | Emory University (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-2390257-A1 | 2'-fluoronucleosides | Emory University (US) | 2011-11-30 | — | — | EP | disclosed |
| US-20110256952-A1 | GOLF CLUB, SHAFT REPLACING METHOD AND HEAD REPLACING METHOD | BRIDGESTONE SPORTS CO., LTD. (JP) | 2011-10-20 | — | — | US | disclosed |
| US-20100173863-A1 | 2-Fluoronucleosides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-07-08 | — | — | US | disclosed |
| US-7662938-B2 | 2′-fluoronucleosides | EMORY UNIVERSITY (US) | 2010-02-16 | — | — | US | disclosed |
| US-20020198171-A1 | 2'-fluoronucleosides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-12-26 | — | — | US | disclosed |
| US-6498251-B1 | Tetrahydrobenzindole derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-12-24 | — | — | US | disclosed |
| US-6355642-B1 | PSYCHOLOGICAL DISORDERS AND BRAIN DISORDERS | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-03-12 | — | — | US | disclosed |
| US-6348587-B1 | PURINE OR PYRIMIDINE BASE DERIVATIVES; ANTICANCER, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS; TREATING HIV AND HEPATITIS | EMORY UNIVERSITY | 2002-02-19 | — | — | US | disclosed |
| US-6159996-A | Polycyclic thiazolidin-2-ylidene amines, process for their preparation, and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-12-12 | — | — | US | disclosed |
| EP-1057814-A1 | TETRAHYDROBENZINDOLE DERIVATIVES | Meiji Seika Kaisha, Ltd. (JP) | 2000-12-06 | — | — | EP | disclosed |
| EP-0937715-A1 | TETRAHYDROBENZINDOLE COMPOUNDS | MEIJI SEIKA KAISHA LTD. (JP) | 1999-08-25 | — | — | EP | disclosed |
| US-5502028-A | Herbicidal pyrimidinyl or triazinyl haloacetic acid derivatives | SCHERING AGROCHEMICALS LIMITED (GB) | 1996-03-26 | — | — | US | disclosed |
| EP-0575404-A1 | HERBICIDES | AgrEvo UK Limited (GB) | 1993-12-29 | — | — | EP | disclosed |
| WO-1992016511-A1 | HERBICIDES | SCHERING AGROCHEMICALS LIMITED (GB) | 1992-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198171-A1 | 2'-fluoronucleosides | NSUN2, PNP, FDPS | AGER 3750/4885MAPT 4794/4885MCOLN3 3061/4885 |
| US-20100173863-A1 | 2-Fluoronucleosides | PNP, BCL3, NPC1 | AGER 4413/4885MAPT 4753/4885MCOLN3 2546/4885 |
| US-20160158266-A1 | 2' FLUORONUCLEOSIDES | PNP, BCL3, NPC1 | AGER 4395/4885MAPT 4745/4885MCOLN3 2385/4885 |
| US-20130157971-A1 | 2'-FLUORONUCLEOSIDES | PNP, BCL3, FUBP3 | AGER 4346/4885MAPT 4760/4885MCOLN3 2158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.